Literature DB >> 21904481

A new look at a mainstay ulcerative colitis therapy.

Charles A Sninsky1, Michael Safdi, Seymour Katz.   

Abstract

Entities:  

Year:  2008        PMID： 21904481      PMCID： PMC3088833     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  38 in total

Review 1.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Authors:  L Sutherland; J K Macdonald
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

3.  The burden of inflammatory bowel disease in the United States: a moving target?

Authors:  Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12       Impact factor: 11.382

4.  The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England.

Authors:  S W Han; E McColl; N Steen; J R Barton; M R Welfare
Journal:  Scand J Gastroenterol       Date:  1998-09       Impact factor: 2.423

5.  Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors:  Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

6.  Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Authors:  P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

7.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

8.  The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

Authors:  Brian G Feagan; Walter Reinisch; Paul Rutgeerts; William J Sandborn; Songkai Yan; Debra Eisenberg; Mohan Bala; Jewel Johanns; Allan Olson; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2007-02-23       Impact factor: 10.864

Review 9.  Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Authors:  W J Sandborn; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

10.  An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.

Authors: 
Journal:  Ann Intern Med       Date:  1996-01-15       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.